We read with interest the Opinion article by Nencioni and colleagues (Fasting and cancer: molecular mechanisms and clinical application. Nat. Rev. Cancer 18, 707-719 (2018) ) 1 on molecular mechanisms involved in the potential application of fasting in oncology. We accept that fasting and calorie restriction may represent an intriguing springboard for developing future strategies with potential benefits in cancer treatment. However, we would like to point out that the clinical application of fasting and fasting-mimicking diets (FMDs) should only be undertaken with extreme caution, and that the media's enthusiasm for this approach is excessive and unjustified.
According to a recent consensus article, while the results obtained by fasting in cellular and animal models might conceivably be transferred to and benefit patients with cancer in terms of treatment response, toxicity and survival remain to be ascertained 2 . Several trials have been underway to determine the potential for short-term fasting (STF) in reducing the side effects and enhancing the efficacy of chemotherapy. However, although a considerable number of these have been completed, the results have not yet been published 3 .
Over the past year, only one pilot crossover trial in 34 patients with gynaecological cancer receiving chemotherapy showed that quality of life impairment was lower during STF than in non-fasted periods 4 . Larger studies to prove the effect of STF as an adjunct to chemotherapy have been lacking, and the need for larger studies has been stressed by several reviews published in the past 8 years 3, [5] [6] [7] [8] [9] [10] . Also, completed and ongoing clinical trials have only excluded patients with low body mass index and patients 3001-3004 (2017) .
